Evidence map›Paper›PMID 29110680›Full record

ArticleVirology journal2017

Fraction of high-grade cervical intraepithelial lesions attributable to genotypes targeted by a nonavalent HPV vaccine in Galicia, Spain.

S Perez, A Iñarrea, R Pérez-Tanoira, M Gil, E López-Díez, O Valenzuela, M Porto, L Alberte-Lista, M A Peteiro-Cancelo, A Treinta and 4 more

Erratum issued Registry-linked trialOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Virology journal, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. It is linked to trial NCT05267834 (In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-type Impact), which is not on this map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT05267834 completednot on this mapstarted 2022, after this paper: background citation

In Situ/Microinvasive Adenocarcinoma of the Uterine Cervix and HPV-type Impact: Pathologic Features, Treatment Options, and Follow-up Outcomes - Cervical Adenocarcinoma Study Group (CAS-Group).

TypeobservationalSponsorUniversità Politecnica delle MarcheRan2022 to 2023Enrolled148ConditionsAdenocarcinoma of the Uterine CervixArmsConization and/or Hysterectomy
3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 1 country.

S PerezMicrobiology Department, Institute of Biomedical Research of Vigo, University Hospital of Vigo, Vigo, Spain. sonia.perez.castro@sergas.es.
A IñarreaGynecology Department, University Hospital of Vigo, Vigo, Spain.
R Pérez-TanoiraInternal Medicine Department, Hospital Fundación Jiménez Díaz, Madrid, Spain.
M GilGynecology Department, University Hospital of Vigo, Vigo, Spain.
E López-DíezUrology Department, University Hospital of Vigo, Vigo, Spain.
O ValenzuelaGynecology Department, University Hospital of Vigo, Vigo, Spain.
M PortoGynecology Department, University Hospital of Vigo, Vigo, Spain.
L Alberte-ListaPathology Department, University Hospital of Vigo, Vigo, Spain.
M A Peteiro-CanceloPathology Department, University Hospital of Vigo, Vigo, Spain.
A TreintaMicrobiology Department, Institute of Biomedical Research of Vigo, University Hospital of Vigo, Vigo, Spain.
R CarballoMicrobiology Department, Institute of Biomedical Research of Vigo, University Hospital of Vigo, Vigo, Spain.
M C ReboredoGynecology Department, University Hospital of Vigo, Vigo, Spain.
M E Alvarez-ArgüellesVirology Department, Central University Hospital of Asturias, Oviedo, Spain.
M J PurriñosHealth and Epidemiology Department. Innovation and management of public health. Consellería de Sanidade, Xunta de Galicia, Santiago de Compostela, A Coruña, Spain.
University Hospital Complex Of Vigo · ESHospital Universitario Central de Asturias · ESHospital Universitario Fundación Jiménez Díaz · ESXunta de Galicia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuman papillomavirus (HPV) bivalent and quadrivalent vaccines have been widely implemented in worldwide organized immunization programs. A nonavalent HPV vaccine is now available in several countries. The objective was to describe the fraction of squamous non-invasive high-grade cervical intraepithelial lesions attributable to genotypes targeted by bi-quadrivalent vaccines and by nonavalent vaccine according to age and diagnosis in women living in the city of Vigo (Galicia, Spain).

methodsCervical scrapings (2009-2014) of women with histological diagnosis of cervical intraepithelial neoplasia grade 2 (CIN2, n = 145) and grade 3-carcinoma in situ (CIN3-CIS, n = 244) were tested with Linear Array HPV Genotyping test (Roche diagnostics, Mannheim, Germany). Hierarchical estimation of the fraction attributable to HPV 16/18 or HPV 31/33/45/52/58 detected alone or in combination was calculated. Absolute additional fraction attributable to genotypes targeted by nonavalent vaccine compared to genotypes targeted by bi-quadrivalent vaccines was calculated as the increment of attributable cases with respect to all studied cases. Age group 1, 2 and 3 included women 18 to 34, 35-44 and ≥45 years old, respectively. EPIDAT 3.1 was used.

resultsFraction attributable to genotypes targeted by bi-quadrivalent vaccines was 59% CIN2 vs. 69% CIN3-CIS (p < 0.001). It was 63/51/50% of CIN2 and 78/66/45% of CIN3-CIS in age group 1, 2, 3, respectively. Fraction attributable to genotypes targeted by nonavalent vaccine was 86% CIN2 and 86% CIN3-CIS. It was 87/91/75% of CIN2 and 90/86/76% of CIN3-CIS in age group 1, 2, 3, respectively. Fraction attributable to genotypes targeted by these vaccines tended to decrease as age increased (p-trend <0.05). Globally, absolute additional attributable fraction was 16%, 26% and 29% in age group 1, 2 and 3, respectively (p < 0.005).

conclusionsAbsolute additional fraction of CIN2 and CIN3-CIS attributable to genotypes targeted by nonavalent vaccine was observed in women of any age, especially in those over 35 years old.

Indexed as

AdultAgedAge FactorsDNA, ViralFemaleGenotypeHumansMiddle AgedNeoplasm GradingPapillomaviridaePapillomavirus InfectionsPapillomavirus VaccinesPrevalenceProspective StudiesSpainUterine Cervical DysplasiaDNA, ViralPapillomavirus VaccinesAdditional impactCervical lesionHPVNonavalent vaccinePotential impact

Identifiers

PMID29110680
PMCPMC5674742
OpenAlexW2767359455

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.